Table 1 Patient demographics, therapy, and response ( N = 225)
Age (years), median (range) | 59.2 (22.6–75.4) |
Gender, n (%) | |
Female | 80 (35.6) |
Male | 145 (64.4) |
ECOG performance status, n (%) | |
0 | 132 (58.7) |
1 | 66 (29.3) |
2 | 19 (8.4) |
Missing | 8 (3.6) |
Multifocal Disease, n (%) | |
Yes | 26 (11.6) |
No | 198 (88) |
Missing | 1 (0.4) |
Extent of tumor resection, n (%) | |
Biopsy | 29 (12.9) |
Partial resection | 104 (46.2) |
Gross total resection | 89 (39.6) |
Missing | 3 (1.3) |
Corticosteroid therapy at initiation of RT/TMZ, n (%) | |
Yes | 165 (73.3) |
No | 57 (25.3) |
Missing | 3 (1.3) |
No. of TMZ cycles following initial RT/TMZ, n (%) | |
Median | 3 |
0 | 36 (16.0) |
1 | 13 (5.8) |
2 | 54 (24.0) |
3 | 12 (5.3) |
4 | 10 (4.4) |
5 | 23 (10.2) |
6 | 75 (33.3) |
Missing | 2 (0.9) |
Reoperation, n (%) | |
Yes | 74 (33.0) |
No | 151 (67.0) |
Second-line TMZ therapy, n (%) | |
Yes | 12 (5.3) |
No | 213 (94.7) |
Second-line BEV/IRI therapy | |
Yes | 85 (37.8) |
No | 132(58.7) |
Missing | 8 (3.6) |
Follow-up duration (months), median (range) | 60 (23–92) |
Best clinical response, n (%) | |
CR | 6 (2.7) |
PR | 17 (7.5) |
SD | 93 (41.3) |
PD | 94 (41.8) |
Missing | 15 (6.7) |